Trial Profile
Comparison of canagliflozin vs. tenegliptin against basic metabolic risks in patients with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CANTABILE study
- 15 Dec 2020 Status changed from active, no longer recruiting to completed.
- 06 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2018 Status changed from not yet recruiting to recruiting.